# Marilyn J Manco-Johnson

List of Publications by Year
in descending order



| 103 | 5,108 | 186265 | 88630 |
|---|---|---|---|
| papers | citations | 28 h-index | 70 g-index |

| 109 | 109 | 109 | 3299 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. New England Journal of Medicine, 2007, 357, 535-544. | 27.0 | 1,681 |
| 2 | Impact of Thrombophilia on Risk of Arterial Ischemic Stroke or Cerebral Sinovenous Thrombosis in Neonates and Children. Circulation, 2010, 121, 1838-1847. | 1.6 | 383 |
| 3 | Phase 3 Study of Recombinant Factor IX Fc Fusion Protein in Hemophilia B. New England Journal of Medicine, 2013, 369, 2313-2323. | 27.0 | 307 |
| 4 | Elevated Plasma Factor VIII and D-Dimer Levels as Predictors of Poor Outcomes of Thrombosis in Children. New England Journal of Medicine, 2004, 351, 1081-1088. | 27.0 | 232 |
| 5 | Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: Validity of the hemophilia joint health score. Arthritis Care and Research, 2011, 63, 223-230. | 3.4 | 224 |
| 6 | Assay of the von Willebrand factor (VWF) propeptide to identify patients with type 1 von Willebrand disease with decreased VWF survival. Blood, 2006, 108, 3344-3351. | 1.4 | 180 |
| 7 | Results of secondary prophylaxis in children with severe hemophilia. American Journal of Hematology, 1994, 47, 113-117. | 4.1 | 156 |
| 8 | A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. Blood, 2007, 110, 45-53. | 1.4 | 138 |
| 9 | Laboratory Testing for Thrombophilia in Pediatric Patients. Thrombosis and Haemostasis, 2002, 88, 155-156. | 3.4 | 122 |
| 10 | Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood, 2017, 129, 2368-2374. | 1.4 | 121 |
| 11 | A new euglobulin clot lysis assay for global fibrinolysis. Thrombosis Research, 2003, 112, 329-337. | 1.7 | 103 |
| 12 | A new global assay of coagulation and fibrinolysis. Thrombosis Research, 2005, 116, 345-356. | 1.7 | 76 |
| 13 | Lupus anticoagulant in children with thrombosis. American Journal of Hematology, 1995, 48, 240-243. | 4.1 | 72 |
| 14 | Athletic Participation in Severe Hemophilia: Bleeding and Joint Outcomes in Children on Prophylaxis. Pediatrics, 2009, 124, 1267-1272. | 2.1 | 68 |
| 15 | Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study. Blood Advances, 2020, 4, 2451-2459. | 5.2 | 67 |
| 16 | 32P Radiosynoviorthesis in Children With Hemophilia. Journal of Pediatric Hematology/Oncology, 2002, 24, 534-539. | 0.6 | 64 |
| 17 | Inflammatory predictors of neurologic disability after preterm premature rupture of membranes. American Journal of Obstetrics and Gynecology, 2015, 212, 212.e1-212.e9. | 1.3 | 56 |
| 18 | Intracranial haemorrhage in children and adolescents with severe haemophilia A or B â€“ the impact of prophylactic treatment. British Journal of Haematology, 2017, 179, 298-307. | 2.5 | 56 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | The factor V Leiden mutation in children with cancer and thrombosis. British Journal of Haematology, 1997, 96, 484-489. | 2.5 | 51 |
| 20 | The Effect of Factor VIII Deficiencies and Replacement and Bypass Therapies on Thrombus Formation under Venous Flow Conditions in Microfluidic and Computational Models. PLoS ONE, 2013, 8, e78732. | 2.5 | 50 |
| 21 | Pediatric Thrombolysis: A Practical Approach. Frontiers in Pediatrics, 2017, 5, 260. | 1.9 | 47 |
| 22 | Disorders of Hemostasis in Childhood: Risk Factors for Venous Thromboembolism. Thrombosis and Haemostasis, 1997, 78, 710-714. | 3.4 | 47 |
| 23 | A cross-sectional analysis of cardiovascular disease in the hemophilia population. Blood Advances, 2018, 2, 1325-1333. | 5.2 | 43 |
| 24 | Effect of Anticoagulant Therapy for 6 Weeks vs 3 Months on Recurrence and Bleeding Events in Patients Younger Than 21 Years of Age With Provoked Venous Thromboembolism. JAMA - Journal of the American Medical Association, 2022, 327, 129. | 7.4 | 37 |
| 25 | The Hemophilia Joint Health Score version 2.1 Validation in Adult Patients Study: A multicenter international study. Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12690. | 2.3 | 37 |
| 26 | Characteristics and Risk Factors of Cancer Associated Venous Thromboembolism. Thrombosis Research, 2015, 136, 535-541. | 1.7 | 30 |
| 27 | Inter-Rater Reliability of the CASCADE Criteria. Stroke, 2016, 47, 2443-2449. | 2.0 | 30 |
| 28 | Protein C concentrate prevents peripartum thrombosis. American Journal of Hematology, 1992, 40, 69-70. | 4.1 | 29 |
| 29 | Clinical causes and treatment of the thrombotic storm. Expert Review of Hematology, 2012, 5, 653-659. | 2.2 | 29 |
| 30 | The prothrombin Denver patient has two different prothrombin point mutations resulting in Gluâ€300â†'Lys and Gluâ€309â†'Lys substitutions. British Journal of Haematology, 2000, 108, 182-187. | 2.5 | 27 |
| 31 | High Prevalence of Thrombophilic Traits in Children with Family History of Thromboembolism. Journal of Pediatrics, 2010, 157, 485-489. | 1.8 | 27 |
| 32 | Practical considerations in choosing a factor VIII prophylaxis regimen: Role of clinical phenotype and trough levels. Thrombosis and Haemostasis, 2016, 115, 913-920. | 3.4 | 27 |
| 33 | Heparin neutralization is essential for accurate measurement of factor VIII activity and inhibitor assays in blood samples drawn from implanted venous access devices. Translational Research, 2000, 136, 74-79. | 2.3 | 26 |
| 34 | Activated Protein C Concentrate Reverses Purpura Fulminans in Severe Genetic Protein C Deficiency. Journal of Pediatric Hematology/Oncology, 2004, 26, 25-27. | 0.6 | 26 |
| 35 | Validation of Upper Extremity Post-Thrombotic Syndrome Outcome Measurement in Children. Journal of Pediatrics, 2010, 157, 852-855. | 1.8 | 26 |
| 36 | Thromboelastographic phenotypes of fibrinogen and its variants: Clinical and non-clinical implications. Thrombosis Research, 2014, 133, 1115-1123. | 1.7 | 23 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Outcome measures in Haemophilia: Beyond ABR (Annualized Bleeding Rate). Haemophilia, 2021, 27, 87-95. | 2.1 | 23 |
| 38 | Pulmonary vascular extraction of circulating norepinephrine in infants with bronchopulmonary dysplasia. Pediatric Pulmonology, 1987, 3, 386-391. | 2.0 | 22 |
| 39 | Update on treatment regimens: Prophylaxis versus on-demand therapy. Seminars in Hematology, 2003, 40, 3-9. | 3.4 | 22 |
| 40 | Identification of a Unique Form of Protein C in the Ovine Fetus: Developmentally Linked Transition to the Adult Form. Pediatric Research, 1995, 37, 365-372. | 2.3 | 21 |
| 41 | Treatment, Survival, and Thromboembolic Outcomes of Thrombotic Storm in Children. Journal of Pediatrics, 2012, 161, 682-688.e1. | 1.8 | 20 |
| 42 | Efficacy and safety of protein C concentrate to treat purpura fulminans and thromboembolic events in severe congenital protein C deficiency. Thrombosis and Haemostasis, 2016, 116, 58-68. | 3.4 | 19 |
| 43 | Musculoskeletal ultrasound in hemophilia: Results and recommendations from a global survey and consensus meeting. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12531. | 2.3 | 18 |
| 44 | Heparin cofactor II in adults and infants with thrombosis and DIC. American Journal of Hematology, 1989, 31, 109-113. | 4.1 | 17 |
| 45 | Differences in Thrombotic Risk Factors in Black and White Women with Adverse Pregnancy Outcome. Thrombosis Research, 2014, 133, 108-111. | 1.7 | 17 |
| 46 | Development of Coagulation Regulatory Proteins in the Fetal and Neonatal Lamb. Pediatric Research, 2002, 52, 580-588. | 2.3 | 16 |
| 47 | Whole blood gene expression profiles distinguish clinical phenotypes of venous thromboembolism. Thrombosis Research, 2015, 135, 659-665. | 1.7 | 16 |
| 48 | Community counts: Evolution of a national surveillance system for bleeding disorders. American Journal of Hematology, 2018, 93, E137-E140. | 4.1 | 15 |
| 49 | Findings of Thrombophilia Evaluation and Impact On Management in Asymptomatic Children with a Proximate Family History of Early Thromboembolism: An Institutional-Based Prospective Inceptional Cohort Study.. Blood, 2009, 114, 1289-1289. | 1.4 | 15 |
| 50 | Evaluating international Haemophilia Joint Health Score (HJHS) results combined with expert opinion: Options for a shorter HJHS. Haemophilia, 2020, 26, 1072-1080. | 2.1 | 14 |
| 51 | Antithrombin deficiency: A pediatric disorder. Thrombosis Research, 2021, 202, 45-51. | 1.7 | 11 |
| 52 | Advances in the Care and Treatment of Children with Hemophilia. Advances in Pediatrics, 2010, 57, 287-294. | 1.4 | 10 |
| 53 | Hyperglycemia-Induced Hyperinsulinemia Decreases Maternal and Fetal Plasma Protein C Concentration during Ovine Gestation. Pediatric Research, 1994, 36, 293-299. | 2.3 | 8 |
| 54 | Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes. Haemophilia, 2019, 25, 867-875. | 2.1 | 8 |

| # | Article | IF | Citations |
|---|---|---|---|
| 55 | Biomarkers of bone disease in persons with haemophilia. Haemophilia, 2021, 27, 149-155. | 2.1 | 8 |
| 56 | Identification of Patients At High Risk for Recurrent Venous Thromboembolism by Whole Blood Gene Expression Analysis. Blood, 2011, 118, 2305-2305. | 1.4 | 8 |
| 57 | Correlation between the Functional Assay for Activated Protein C Resistance and Factor V Leiden in the Neonate. Pediatric Research, 1997, 42, 776-778. | 2.3 | 7 |
| 58 | Validity and reliability of the Colorado Adult Joint Assessment Scale in adults with moderateâ€severe hemophilia A. Journal of Thrombosis and Haemostasis, 2020, 18, 285-294. | 3.8 | 6 |
| 59 | Disseminated Intravascular Coagulation Is an Independent Predictor of Adverse Outcomes in Children in the Emergency Department with Suspected Sepsis. Journal of Pediatrics, 2020, 225, 198-206.e2. | 1.8 | 6 |
| 60 | Antiphospholipid Antibodies Increase Von Willebrand Factor-Platelet String Formation From Human Endothelial Cells Under Physiologic Flow Conditions. Blood, 2013, 122, 2305-2305. | 1.4 | 6 |
| 61 | Factor VIIa treatment increases circulating extracellular vesicles in hemophilia patients: Implications for the therapeutic hemostatic effect of FVIIa. Journal of Thrombosis and Haemostasis, 2022, 20, 1928-1933. | 3.8 | 6 |
| 62 | FVIII/VWF ratio is not a reliable predictor of VWD in children. Pediatric Blood and Cancer, 2014, 61, 936-939. | 1.5 | 5 |
| 63 | Variants in chondroitin sulfate metabolism genes in thrombotic storm. Thrombosis Research, 2018, 161, 43-51. | 1.7 | 5 |
| 64 | Validation of Outcome Instruments for Pediatric Postthrombotic Syndrome: Introducing the Peds-VEINES-QOL, a New Health-Related Quality of Life Instrument. Thrombosis and Haemostasis, 2021, 121, 1367-1375. | 3.4 | 5 |
| 65 | Biomarkers Of Bone Disease In Subjects With Hemophilia. Blood, 2013, 122, 1113-1113. | 1.4 | 5 |
| 66 | Breakthrough Bleeding in Hemophilia a Patients on Prophylaxis. Blood, 2016, 128, 2581-2581. | 1.4 | 5 |
| 67 | The Kids-DOTT Trial: Novel Aspects of the â€˜Parallel Cohort RCTâ€˜ Design and Its Application to the Investigation of Duration of Anticoagulant Therapy for Pediatric Venous Thromboembolism.. Blood, 2009, 114, 4169-4169. | 1.4 | 4 |
| 68 | Effect of Hyperinsulinemia on the Development of Blood Coagulation in the Lamb Fetus. Pediatric Research, 1995, 38, 169-172. | 2.3 | 3 |
| 69 | Effect on Joint Health of Routine Prophylaxis with Bayerâ€™s Sucrose-Formulated Recombinant Factor VIII (rFVIII-FS) in Adolescents and Adults Previously Treated on Demand: MRI Analyses from the 3-Year Spinart Study. Blood, 2014, 124, 2854-2854. | 1.4 | 3 |
| 70 | Current challenges for men and women with mildâ€toâ€moderate haemophilia. Haemophilia, 2021, 27, 5-7. | 2.1 | 2 |
| 71 | Natural History Of Inhibitor Recurrence Following Successful Immune Tolerance Induction. Blood, 2013, 122, 1106-1106. | 1.4 | 2 |
| 72 | Joint Bleeding Patterns in Patients Treated Prophylactically with an Extended Half-Life, Pegylated, Full-Length Recombinant Factor VIII (BAX 855). Blood, 2015, 126, 2300-2300. | 1.4 | 2 |

| # | Article | IF | Citations |
|---|---|---|---|
| 73 | Novel characteristics of soluble fibrin: hypercoagulability and acceleration of blood sedimentation rate mediated by its generation of erythrocyte-linked fibers. Cell and Tissue Research, 2022, 387, 479-491. | 2.9 | 2 |
| 74 | Comorbidities, Health-Related Quality of Life, Health-care Utilization in Older Persons with Hemophiliaâ€"Hematology Utilization Group Study Part VII (HUGS VII). Journal of Blood Medicine, 2022, Volume 13, 229-241. | 1.7 | 2 |
| 75 | Post-Thrombotic Syndrome (PTS) in Children: A Systematic Review of Prevalence, Validity of Outcome Measures, and Prognostic Factors.. Blood, 2009, 114, 2978-2978. | 1.4 | 1 |
| 76 | A Prospective, Multi-Center, Randomized Clinical Trial to Compare the Pharmacokinetic Properties of Human-Cl rhFVIII, a New Human-Cell Line Derived Recombinant Factor VIII, with Those of a Full-Length Recombinant Factor VIII Expressed in Baby Hamster Kidney Cells,. Blood, 2011, 118, 3309-3309. | 1.4 | 1 |
| 77 | Prompt Immune Tolerance Induction at Inhibitor Diagnosis Regardless of Titer May Increase Overall Success in Hemophilia A With Inhibitors: Experience of Two US Centers. Blood, 2013, 122, 575-575. | 1.4 | 1 |
| 78 | Evaluation of Physiologic and Pathologic Alterations of Coagulation and Fibrinolysis Using a New Global Assay.. Blood, 2004, 104, 2985-2985. | 1.4 | 1 |
| 79 | Early Findings on the Use of Motion Capture during Simulated Sports Activities to Better Understand Hemophilic Arthropathy. Blood, 2021, 138, 3203-3203. | 1.4 | 1 |
| 80 | Application of Thrombomodulin-Thrombin Generation to Diverse Abnormalities of the Protein C System. Blood, 2020, 136, 31-32. | 1.4 | 1 |
| 81 | When the cause of clotting is not in the bloodâ€"It may be the vessel!. Pediatric Blood and Cancer, 2008, 51, 161-162. | 1.5 | 0 |
| 82 | Severe thrombophilias. , 0, , 166-179. | | 0 |
| 83 | New anticoagulants in children: A review of recent studies and a look to the future. , 0, , 200-206. | | 0 |
| 84 | Prophylaxis for children with moderate hemophilia: Use of a guideline to increase early initiation. Pediatric Blood and Cancer, 2021, 68, e28577. | 1.5 | 0 |
| 85 | Improvements in Communication and Coordination of Care in a Hemophilia Treatment Center. Acta Haematologica, 2021, 144, 672-677. | 1.4 | 0 |
| 86 | Impact of Thrombophilia On Arterial Ischemic Stroke or Cerebral Venous Sinus Thromboses in Children: A Systematic Review & Meta-Analysis of Observational Studies.. Blood, 2009, 114, 3993-3993. | 1.4 | 0 |
| 87 | Afibrinogenemia: a Disorder of Paradoxical Bleeding and Clotting.. Blood, 2009, 114, 3477-3477. | 1.4 | 0 |
| 88 | Racial Differences in Thrombotic Risk Factors Associated with Adverse Pregnancy Outcome Among Women Obtaining Care in US Thrombosis and Hemostasis Centers.. Blood, 2009, 114, 2982-2982. | 1.4 | 0 |
| 89 | The CDC Hemostasis and Thrombosis Centers (HTC) Pilot Sites: Data From the Pediatric Registry.. Blood, 2009, 114, 2990-2990. | 1.4 | 0 |
| 90 | Assessment of Global Hypercoagulability and Fibrinolytic Potential in Pediatric VTE: Findings From A Single-Institutional Prospective Inceptional Cohort Study.. Blood, 2009, 114, 2988-2988. | 1.4 | 0 |

| # | Article | IF | Citations |
|---|---|---|---|
| 91 | Risk Factors for Inhibitor Development in Mild and Moderate Hemophilia A: A Case-Control Study.. Blood, 2009, 114, 3184-3184. | 1.4 | 0 |
| 92 | Intra-Abdominal Venous Thrombosis: Characteristics of Pediatric and Adult Patients. Blood, 2010, 116, 4219-4219. | 1.4 | 0 |
| 93 | Continued Transmission of Parvovirus B19 in Plasma-Derived Factor Concentrates After the Implementation of B19 Nucleic Acid Plasma Minipool Screening,. Blood, 2011, 118, 3378-3378. | 1.4 | 0 |
| 94 | A Novel Missense Mutation in FGG (c.944C>A) Encodes for An Amino Acid Change (p.Ala315Asp) in the Gamma Chain of Fibrinogen Causing Hypofibrinogenemia and a Thrombotic Phenotype. Blood, 2011, 118, 856-856. | 1.4 | 0 |
| 95 | Findings of Feasibility Assessment From Multicenter Clinical Trials of Antithrombotic Therapy in Pediatric Venous Thromboembolism. Blood, 2011, 118, 4323-4323. | 1.4 | 0 |
| 96 | Whole-Exome Sequencing Identifies Novel Risk Variant for Thrombotic Storm. Blood, 2011, 118, 1229-1229. | 1.4 | 0 |
| 97 | Consequences of Switching From Prophylactic Treatment to On-Demand Treatment in Late Teens and Early Adults with Severe Hemophilia A. the TEEN/TWEN Study. Blood, 2011, 118, 2288-2288. | 1.4 | 0 |
| 98 | Registry Of Patients Treated With Protein C Concentrate (Human) In The United States and Europe: Interim Results. Blood, 2013, 122, 1146-1146. | 1.4 | 0 |
| 99 | Pilot/Feasibility Metrics, Real-Time Remote Monitoring, and Inter-Observer Agreement on Veno-Occlusion in a National Multicenter Randomized Controlled Trial of Pediatric Venous Thromboembolism: Findings from the Pilot/Feasibility Phase of the Kids-DOTT Trial. Blood, 2014, 124, 4271-4271. | 1.4 | 0 |
| 100 | Use of Institutional Clinical Care Guidelines to Determine HA-VTE Risk Level for Consideration of Thromboprophylaxis in Hospitalized Children. Blood, 2015, 126, 3276-3276. | 1.4 | 0 |
| 101 | Outcomes of Severe Hemophilia a Patients on Continuous Prophylaxis Relative to Inhibitor Status in the Community Counts Registry. Blood, 2016, 128, 1405-1405. | 1.4 | 0 |
| 102 | Association of Hemophilia a Inhibitor Status and Patient-Reported Outcomes with Work Productivity and Health-Related Quality of Life. Blood, 2021, 138, 4069-4069. | 1.4 | 0 |
| 103 | Impact of Hemophilia a Inhibitor on Joint Health and Health-Related Quality of Life from the Hemophilia Utilization Group Studies Part VIII in the U.S. Blood, 2020, 136, 8-9. | 1.4 | 0 |